Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.

PMID:
23964933
[PubMed - indexed for MEDLINE]
Free Article
2.

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group.

N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.

PMID:
23964932
[PubMed - indexed for MEDLINE]
Free Article
3.

A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.

Stollman N, Magowan S, Shanahan F, Quigley EM; DIVA Investigator Group.

J Clin Gastroenterol. 2013 Aug;47(7):621-9. doi: 10.1097/MCG.0b013e31828003f6.

PMID:
23426454
[PubMed - indexed for MEDLINE]
4.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group.

N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.

PMID:
21208106
[PubMed - indexed for MEDLINE]
Free Article
5.

Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.

Safdi AV, Cohen RD.

Aliment Pharmacol Ther. 2007 Nov 1;26(9):1179-86. Review.

PMID:
17944732
[PubMed - indexed for MEDLINE]
Free Article
6.

Residue-free sodium phosphate tablets (OsmoPrep) versus Visicol for colon cleansing: a randomized, investigator-blinded trial.

Wruble L, Demicco M, Medoff J, Safdi A, Bernstein J, Dalke D, Rose M, Karlstadt RG, Ettinger N, Zhang B.

Gastrointest Endosc. 2007 Apr;65(4):660-70. Epub 2006 Dec 14.

PMID:
17173912
[PubMed - indexed for MEDLINE]
7.

Misoprostol in the treatment of duodenal ulcer refractory to H2-blocker therapy. A placebo-controlled, multicenter, double-blind, randomized trial.

Newman RD, Gitlin N, Lacayo EJ, Safdi AV, Ramsey EJ, Engel SL, Rubin A, Nissen CH, Swabb EA.

Am J Med. 1987 Jul 27;83(1A):27-31.

PMID:
2887112
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk